Internal Reference Number: FOI_6289
Date Request Received: 10/09/2021 00:00:00
Date Request Replied To: 11/11/2021 00:00:00
This response was sent via: By Email
Request Summary: Usage of Biologic drugs
Request Category: Companies
Question Number 1: Could you please provide the numbers of patients treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs: • Adalimumab - Humira • Adalimumab Biosimilar • Filgotinib • Golimumab • Infliximab - Remicade • Infliximab Biosimilar • Tofacitinib • Ustekinumab • Vedolizumab | |
Answer To Question 1: Adalimumab - Humira 6 Adalimumab - Biosimilar 62 Filgotinib 0 Golimumab 2 Infliximab - Remicade 7 Infliximab - Biosimilar 114 Tofacitinib 1 Ustekinumab 34 Vedolizumab 36 | |
Question Number 2: How many patients were treated in the last 3 months for Crohn’s Disease ONLY with the following biologic drugs: • Adalimumab - Humira • Adalimumab Biosimilar • Golimumab • Infliximab - Remicade • Infliximab Biosimilars • Ustekinumab • Vedolizumab | |
Answer To Question 2: Adalimumab (Humeria) 9 Adalimumab (biosimilar) 62 Infliximab 5 Inflectra (infliximab biosimilar) 59 Golimumab 0 (not for Crohns patients) Ustekinumab 33 Vedolizumab 12 | |
To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.